Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Owens & Minor (OMI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 5.13% and 3.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Lags Q3 Earnings Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of -2.27% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Down 16.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

NuVasive (NUVA) Lags Q2 Earnings Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MedTech Stocks to Watch for Earnings on Aug 3

by Zacks Equity Research

MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.

Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline

by Zacks Equity Research

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

NuVasive (NUVA) to Expand in APAC With New Experience Center

by Zacks Equity Research

NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.

Why Is Perrigo (PRGO) Up 13.4% Since Last Earnings Report?

by Zacks Equity Research

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) Up 21.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.

Why Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report?

by Zacks Equity Research

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up

by Zacks Equity Research

Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

by Urmimala Biswas

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Riya Anand headshot

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

by Riya Anand

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.

Why Is NuVasive (NUVA) Down 2.2% Since Last Earnings Report?

by Zacks Equity Research

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

NuVasive (NUVA) Q4 Earnings Lag Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.